desloratadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H1 receptor antagonists, tricyclic compounds	814	100643-71-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: SCH-34117 SCH 34117 desloratadine azomyr delopedil descarboethoxyloratadine descarboethoxyloratidine neoclarityn	major metabolite of loratadine Molecular weight: 310.83 Formula: C19H19ClN2 CLOGP: 3.83 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 24.92 ALOGS: -4.90 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

SCH-34117
SCH 34117
desloratadine
azomyr
delopedil
descarboethoxyloratadine
descarboethoxyloratidine
neoclarityn

major metabolite of loratadine

Molecular weight: 310.83
Formula: C19H19ClN2
CLOGP: 3.83
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 24.92
ALOGS: -4.90
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.23 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 2001	FDA	MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	155.88	12.39	111	14820	37565	50552628
Urticaria	109.23	12.39	161	14770	129400	50460793
Drug reaction with eosinophilia and systemic symptoms	58.79	12.39	56	14875	28368	50561825
Allergy test positive	52.82	12.39	14	14917	391	50589802
Erythema	50.17	12.39	124	14807	146290	50443903
Hyponatraemia	48.34	12.39	95	14836	96044	50494149
Toxic skin eruption	43.86	12.39	32	14899	11219	50578974
Pruritus	43.44	12.39	182	14749	283386	50306807
Hallucination, auditory	42.93	12.39	31	14900	10697	50579496
Dermatitis bullous	41.35	12.39	26	14905	7147	50583046
Haemangioma congenital	37.99	12.39	11	14920	428	50589765
Death	37.54	12.39	25	14906	325354	50264839
Terminal dribbling	36.53	12.39	6	14925	11	50590182
Eczema	34.69	12.39	38	14893	22664	50567529
Paranoia	32.76	12.39	26	14905	10322	50579871
Rheumatoid arthritis	31.97	12.39	10	14921	202540	50387653
Drug intolerance	30.88	12.39	13	14918	219091	50371102
Victim of chemical submission	29.17	12.39	8	14923	255	50589938
Blood immunoglobulin E increased	28.72	12.39	14	14917	2345	50587848
Completed suicide	28.27	12.39	3	14928	131886	50458307
Intentional overdose	28.11	12.39	59	14872	62445	50527748
Cerebral thrombosis	27.54	12.39	12	14919	1556	50588637
Face oedema	27.50	12.39	30	14901	17809	50572384
Intentional self-injury	27.47	12.39	34	14897	23078	50567115
Nasal ulcer	26.72	12.39	12	14919	1671	50588522
Systemic lupus erythematosus	25.96	12.39	5	14926	140617	50449576
Tooth injury	25.82	12.39	10	14921	961	50589232
Skin dystrophy	25.26	12.39	5	14926	35	50590158
Type IV hypersensitivity reaction	25.13	12.39	13	14918	2469	50587724
Aggression	24.99	12.39	31	14900	21085	50569108
Oxalosis	24.56	12.39	5	14926	41	50590152
Gestational hypertension	23.80	12.39	12	14919	2161	50588032
Somnolence	23.29	12.39	99	14832	154886	50435307
Urticaria thermal	22.59	12.39	6	14925	169	50590024
Drug ineffective	22.43	12.39	146	14785	819187	49771006
Burn oral cavity	22.40	12.39	5	14926	66	50590127
Hyperkalaemia	22.33	12.39	46	14885	48043	50542150
Endocrine ophthalmopathy	22.18	12.39	7	14924	366	50589827
Joint swelling	21.96	12.39	24	14907	245262	50344931
Wound	21.21	12.39	3	14928	105791	50484402
Tongue oedema	19.86	12.39	13	14918	3826	50586367
Synovitis	19.74	12.39	6	14925	123859	50466334
Dermatitis exfoliative generalised	19.72	12.39	12	14919	3114	50587079
Hyperoxaluria	19.32	12.39	5	14926	127	50590066
Therapeutic product effect decreased	19.27	12.39	8	14923	136042	50454151
Hepatocellular injury	18.65	12.39	30	14901	25917	50564276
Inflammatory bowel disease	18.63	12.39	12	14919	3438	50586755
Acute kidney injury	18.59	12.39	123	14808	227935	50362258
Guttate psoriasis	18.21	12.39	6	14925	360	50589833
Treatment failure	18.08	12.39	9	14922	137628	50452565
Nightmare	18.06	12.39	23	14908	16063	50574130
HLA-B*27 positive	17.28	12.39	5	14926	194	50589999
Rash erythematous	16.96	12.39	34	14897	34818	50555375
Eosinophilia	16.86	12.39	24	14907	18628	50571565
Keratopathy	16.77	12.39	6	14925	462	50589731
Rash maculo-papular	16.73	12.39	29	14902	26612	50563581
Urine oxalate increased	16.42	12.39	5	14926	232	50589961
Pain	16.38	12.39	102	14829	578801	50011392
Arteriospasm coronary	16.34	12.39	11	14920	3391	50586802
Upper respiratory tract infection bacterial	16.18	12.39	4	14927	84	50590109
Asthma	15.75	12.39	60	14871	89277	50500916
Arrhythmia	15.74	12.39	32	14899	33100	50557093
Abortion	15.61	12.39	9	14922	2115	50588078
Photosensitivity reaction	15.35	12.39	19	14912	12892	50577301
Patent ductus arteriosus	15.19	12.39	11	14920	3809	50586384
Subretinal haematoma	15.15	12.39	3	14928	21	50590172
Nasal pruritus	14.96	12.39	5	14926	314	50589879
Amnestic disorder	14.96	12.39	5	14926	314	50589879
Hypersensitivity pneumonitis	14.87	12.39	9	14922	2313	50587880
Lip oedema	14.57	12.39	10	14921	3183	50587010
Intraocular haematoma	14.49	12.39	3	14928	27	50590166
Food intolerance	14.44	12.39	9	14922	2435	50587758
Feeling hot	14.24	12.39	34	14897	39168	50551025
Anaphylactic shock	14.07	12.39	23	14908	20132	50570061
Psychotic disorder	14.04	12.39	24	14907	21788	50568405
Contraindicated product administered	13.96	12.39	14	14917	148944	50441249
Vitamin D deficiency	13.91	12.39	17	14914	11385	50578808
Onycholysis	13.57	12.39	7	14924	1321	50588872
Pharyngeal oedema	13.49	12.39	18	14913	13147	50577046
White blood cell count decreased	13.38	12.39	9	14922	116713	50473480
Fixed eruption	13.38	12.39	6	14925	833	50589360
Systolic hypertension	13.36	12.39	5	14926	437	50589756
Hepatic cytolysis	13.14	12.39	14	14917	8089	50582104
Drug dose titration not performed	13.13	12.39	5	14926	459	50589734
Pancoast's syndrome	13.08	12.39	3	14928	45	50590148
Product use in unapproved indication	13.00	12.39	68	14863	115751	50474442
Eyelid erosion	12.96	12.39	3	14928	47	50590146
Toxic shock syndrome	12.84	12.39	5	14926	487	50589706
Vertigo	12.82	12.39	39	14892	51793	50538400
Swelling	12.73	12.39	25	14906	200847	50389346
Urticaria chronic	12.68	12.39	5	14926	504	50589689
Hernia hiatus repair	12.68	12.39	3	14928	52	50590141
Hepatic lesion	12.53	12.39	10	14921	3998	50586195

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Eosinophilia	58.12	14.10	47	7532	22114	29544834
Toxic skin eruption	52.14	14.10	32	7547	9725	29557223
Rash maculo-papular	50.34	14.10	45	7534	24244	29542704
Dermatitis bullous	46.66	14.10	25	7554	5881	29561067
Death	41.49	14.10	18	7561	342066	29224882
Hepatic haematoma	40.68	14.10	11	7568	384	29566564
Xerosis	38.33	14.10	11	7568	479	29566469
Hyperkaliuria	37.67	14.10	8	7571	96	29566852
Intentional overdose	36.30	14.10	47	7532	38481	29528467
Eczema	35.55	14.10	29	7550	13797	29553151
Corneal abscess	35.06	14.10	6	7573	19	29566929
Urticaria	32.98	14.10	54	7525	54606	29512342
Electrocardiogram QT prolonged	32.36	14.10	43	7536	36094	29530854
Pruritus	30.73	14.10	82	7497	116767	29450181
Rash pustular	29.25	14.10	17	7562	4674	29562274
Miosis	27.61	14.10	20	7559	7989	29558959
Purpura	25.08	14.10	20	7559	9212	29557736
Blood immunoglobulin E decreased	25.05	14.10	5	7574	43	29566905
Keratitis	25.04	14.10	10	7569	1202	29565746
Angioedema	24.11	14.10	35	7544	31880	29535068
Acute generalised exanthematous pustulosis	24.08	14.10	16	7563	5567	29561381
Cholangiocarcinoma	23.74	14.10	9	7570	941	29566007
Prurigo	23.57	14.10	8	7571	608	29566340
Oedema genital	23.21	14.10	7	7572	363	29566585
Arrhythmia	23.16	14.10	34	7545	31279	29535669
Oral dysaesthesia	22.15	14.10	5	7574	81	29566867
Bulbar palsy	21.57	14.10	6	7573	233	29566715
Eyelid ptosis congenital	21.55	14.10	5	7574	92	29566856
Type III immune complex mediated reaction	21.21	14.10	6	7573	248	29566700
Myoglobin blood increased	20.25	14.10	10	7569	1985	29564963
Dermatitis exfoliative	19.80	14.10	15	7564	6410	29560538
Pemphigoid	19.69	14.10	16	7563	7565	29559383
Dermatitis psoriasiform	18.79	14.10	8	7571	1130	29565818
Hepatic cytolysis	18.35	14.10	16	7563	8331	29558617
Retinopathy	18.23	14.10	9	7570	1786	29565162
Spermatic cord disorder	17.65	14.10	3	7576	9	29566939
Rhinitis allergic	17.48	14.10	10	7569	2670	29564278
Hyperlipasaemia	17.36	14.10	6	7573	481	29566467
Rhabdomyolysis	17.31	14.10	44	7535	60764	29506184
Hypertrophic cardiomyopathy	17.28	14.10	7	7572	872	29566076
Wrong product administered	17.20	14.10	12	7567	4519	29562429
Purulent pericarditis	16.98	14.10	3	7576	12	29566936
Rash erythematous	16.80	14.10	24	7555	21538	29545410
Vasoplegia syndrome	16.63	14.10	8	7571	1500	29565448
Intentional self-injury	16.34	14.10	18	7561	12443	29554505
Wrong patient received product	16.19	14.10	9	7570	2273	29564675
Coma	16.18	14.10	33	7546	39417	29527531
Asthma	15.93	14.10	30	7549	33819	29533129
Disease prodromal stage	15.84	14.10	3	7576	19	29566929
Cerebral venous thrombosis	15.78	14.10	6	7573	632	29566316
Pemphigus	15.37	14.10	7	7572	1161	29565787
Neonatal pneumonia	15.04	14.10	4	7575	131	29566817
Vascular cognitive impairment	14.53	14.10	3	7576	31	29566917

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	137.39	11.93	127	19010	61694	64417901
Urticaria	131.99	11.93	189	18948	147128	64332467
Toxic skin eruption	82.13	11.93	58	19079	19226	64460369
Dermatitis bullous	80.28	11.93	48	19089	12006	64467589
Pruritus	72.21	11.93	230	18907	312170	64167425
Eosinophilia	69.06	11.93	70	19067	38006	64441589
Eczema	67.81	11.93	62	19075	29658	64449937
Death	66.66	11.93	30	19107	482675	63996920
Rash maculo-papular	58.56	11.93	71	19066	46955	64432640
Allergy test positive	56.43	11.93	15	19122	421	64479174
Hallucination, auditory	43.93	11.93	38	19099	16901	64462694
Erythema	43.37	11.93	138	18999	186932	64292663
Drug reaction with eosinophilia and systemic symptoms	43.32	11.93	66	19071	54151	64425444
Completed suicide	39.66	11.93	9	19128	224405	64255190
Arrhythmia	37.52	11.93	61	19076	52883	64426712
Terminal dribbling	36.49	11.93	6	19131	11	64479584
Hyponatraemia	35.81	11.93	111	19026	148228	64331367
Rash erythematous	35.78	11.93	57	19080	48576	64431019
Electrocardiogram QT prolonged	35.45	11.93	75	19062	79373	64400222
Face oedema	35.16	11.93	40	19097	24721	64454874
Somnolence	32.50	11.93	133	19004	203512	64276083
Aggression	32.40	11.93	53	19084	46179	64433416
Hyperkaliuria	32.35	11.93	8	19129	167	64479428
Hepatic cytolysis	31.44	11.93	29	19108	14020	64465575
Hepatic haematoma	31.07	11.93	11	19126	817	64478778
Intentional overdose	30.29	11.93	76	19061	89868	64389727
Blood immunoglobulin E increased	30.08	11.93	17	19120	3827	64475768
Corneal abscess	28.65	11.93	6	19131	57	64479538
Drug intolerance	28.65	11.93	10	19127	187982	64291613
Victim of chemical submission	28.08	11.93	8	19129	292	64479303
Nasal ulcer	27.78	11.93	12	19125	1514	64478081
Gestational hypertension	26.67	11.93	12	19125	1669	64477926
Cerebral thrombosis	26.65	11.93	13	19124	2169	64477426
Nightmare	26.62	11.93	32	19105	20961	64458634
Rheumatoid arthritis	26.33	11.93	8	19129	164286	64315309
Acute generalised exanthematous pustulosis	25.76	11.93	26	19111	14032	64465563
Xerosis	25.70	11.93	10	19127	967	64478628
Oedema genital	24.64	11.93	8	19129	456	64479139
Paranoia	24.21	11.93	27	19110	16325	64463270
Hepatocellular injury	24.11	11.93	46	19091	45189	64434406
Skin dystrophy	23.92	11.93	5	19132	47	64479548
Type IV hypersensitivity reaction	23.75	11.93	14	19123	3408	64476187
Prurigo	23.58	11.93	10	19127	1207	64478388
Burn oral cavity	22.81	11.93	5	19132	60	64479535
Tooth injury	22.49	11.93	10	19127	1353	64478242
Urticaria thermal	22.38	11.93	6	19131	174	64479421
Vertigo	22.14	11.93	52	19085	58959	64420636
Endocrine ophthalmopathy	21.34	11.93	7	19130	412	64479183
Hyperkalaemia	21.07	11.93	72	19065	101057	64378538
HLA-B*27 positive	20.97	11.93	5	19132	89	64479506
Oxalosis	20.33	11.93	5	19132	102	64479493
Abortion	20.17	11.93	9	19128	1227	64478368
Bulbar palsy	20.16	11.93	6	19131	256	64479339
Miosis	19.80	11.93	22	19115	13244	64466351
Purpura	19.79	11.93	25	19112	17221	64462374
Platelet count decreased	19.35	11.93	13	19124	167698	64311897
Type III immune complex mediated reaction	19.16	11.93	7	19130	569	64479026
Asthma	19.15	11.93	67	19070	95158	64384437
Tongue oedema	18.78	11.93	15	19122	5975	64473620
Rhinitis allergic	18.71	11.93	17	19120	8061	64471534
Serum amyloid A protein increased	18.65	11.93	5	19132	145	64479450
White blood cell count decreased	18.52	11.93	12	19125	157825	64321770
Cholestasis	18.45	11.93	41	19096	44831	64434764
Inflammatory bowel disease	17.83	11.93	13	19124	4525	64475070
Guttate psoriasis	17.64	11.93	6	19131	395	64479200
Sepsis	17.26	11.93	26	19111	230315	64249280
Rhabdomyolysis	17.13	11.93	63	19074	91663	64387932
Cerebral venous thrombosis	16.98	11.93	10	19127	2431	64477164
Dermatitis exfoliative	16.91	11.93	18	19119	10334	64469261
Dermatitis exfoliative generalised	16.83	11.93	14	19123	5902	64473693
Keratitis	16.78	11.93	11	19126	3226	64476369
Acute kidney injury	16.67	11.93	205	18932	449035	64030560
Urine oxalate increased	16.54	11.93	5	19132	225	64479370
Pancreatitis acute	16.33	11.93	38	19099	42817	64436778
Cholangiocarcinoma	15.99	11.93	9	19128	2009	64477586
Myoglobin blood increased	15.89	11.93	10	19127	2737	64476858
Rash pustular	15.81	11.93	17	19120	9868	64469727
Feeling hot	15.80	11.93	39	19098	45624	64433971
Photosensitivity reaction	15.76	11.93	23	19114	18150	64461445
Hyperoxaluria	15.73	11.93	5	19132	266	64479329
Arteriospasm coronary	15.69	11.93	13	19124	5452	64474143
Hyperlipasaemia	15.36	11.93	7	19130	1003	64478592
Hypersensitivity vasculitis	15.21	11.93	14	19123	6747	64472848
Anaphylactic shock	15.13	11.93	30	19107	30298	64449297
Upper respiratory tract infection bacterial	15.06	11.93	4	19133	112	64479483
Disease progression	15.02	11.93	12	19125	141668	64337927
Onycholysis	14.95	11.93	8	19129	1618	64477977
Therapeutic product effect incomplete	14.92	11.93	6	19131	103476	64376119
Lip oedema	14.18	11.93	12	19125	5177	64474418
Retinopathy	14.04	11.93	10	19127	3355	64476240
Vascular cognitive impairment	13.93	11.93	3	19134	33	64479562
Synovitis	13.88	11.93	6	19131	99084	64380511
Altered state of consciousness	13.78	11.93	33	19104	37869	64441726
Drug level increased	13.78	11.93	31	19106	34165	64445430
Keratopathy	13.76	11.93	6	19131	774	64478821
Oral dysaesthesia	13.71	11.93	4	19133	159	64479436
Pemphigoid	13.61	11.93	18	19119	12968	64466627
Coronavirus infection	13.52	11.93	12	19125	5518	64474077
Urticaria chronic	13.24	11.93	5	19132	446	64479149
Therapeutic product effect decreased	13.22	11.93	9	19128	115342	64364253
Dermatitis psoriasiform	12.89	11.93	8	19129	2138	64477457
Cryopyrin associated periodic syndrome	12.77	11.93	3	19134	50	64479545
Nutritional condition abnormal	12.54	11.93	6	19131	960	64478635
Hyperthermia	12.51	11.93	19	19118	15531	64464064
Febrile neutropenia	12.37	11.93	23	19114	187634	64291961
Purulent pericarditis	12.25	11.93	3	19134	60	64479535
Acute haemorrhagic oedema of infancy	12.25	11.93	3	19134	60	64479535
Amnestic disorder	12.20	11.93	5	19132	554	64479041
Hypersensitivity pneumonitis	12.11	11.93	9	19128	3223	64476372
Eyelid erosion	11.98	11.93	3	19134	66	64479529
Neutrophil count decreased	11.93	11.93	4	19133	77192	64402403

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R06AX27	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Other antihistamines for systemic use
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D039563	Histamine H1 Antagonists, Non-Sedating
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:50857	anti-allergic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic urticaria	indication	40178009	DOID:10612
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Chronic idiopathic urticaria	indication	302162004
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Diabetes mellitus	contraindication	73211009	DOID:9351
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.92	Basic
pKa2	2.48	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.40	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.91	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.96	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.03	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.55	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.80	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.00	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.01	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.19	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.97	DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		IC50	4.80	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.74	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.60	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.49	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.70	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.30	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.51	DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.37	WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.70	DRUG MATRIX

External reference:

ID	Source
4021292	VUID
N0000148729	NUI
D03693	KEGG_DRUG
275635	RXNORM
4021292	VANDF
C0908935	UMLSCUI
CHEBI:291342	CHEBI
CHEMBL1172	ChEMBL_ID
DB00967	DRUGBANK_ID
C121345	MESH_SUPPLEMENTAL_RECORD_UI
124087	PUBCHEM_CID
7157	IUPHAR_LIGAND_ID
7817	INN_ID
FVF865388R	UNII
16243	MMSL
42606	MMSL
51632	MMSL
83662	MMSL
d04785	MMSL
009081	NDDF
134506008	SNOMEDCT_US
396015008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	21695-815	TABLET, FILM COATED	5 mg	ORAL	NDA	23 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-240	TABLET	5 mg	ORAL	ANDA	26 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0765	TABLET, FILM COATED	5 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3975	TABLET	5 mg	ORAL	ANDA	30 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4794	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4624	TABLET, FILM COATED	5 mg	ORAL	NDA	12 sections
Clarinex-D 12 Hour	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5708	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-360	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	55111-551	TABLET, ORALLY DISINTEGRATING	2.50 mg	ORAL	ANDA	26 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	62250-619	TABLET	5 mg	ORAL	ANDA	25 sections
Desloratadine	Human Prescription Drug Label	1	62756-523	TABLET, FILM COATED	5 mg	ORAL	ANDA	28 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-153	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Desloratadine	HUMAN PRESCRIPTION DRUG LABEL	1	69543-107	TABLET	5 mg	ORAL	ANDA	29 sections
DESLORATADINE	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1000	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
Clarinex	HUMAN PRESCRIPTION DRUG LABEL	1	78206-119	TABLET, FILM COATED	5 mg	ORAL	NDA	30 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections
CLARINEX-D 12 HOUR	HUMAN PRESCRIPTION DRUG LABEL	2	78206-120	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	29 sections